The Samuel Waxman Cancer Research Foundation awards $1.54 million in research grants for 2010-2011

July 13, 2010

The Samuel Waxman Cancer Research Foundation (SWCRF) has awarded 13 collaborative research grants and 3 individual research grants, totaling $1.54 million. The 16 grants represent a portion of the science grant program at the Foundation, which will award more than $2 million this year to cancer research. The grant recipients represent some of the best scientific minds in differentiation therapy--reprogramming cancer cells--a hallmark of the Waxman Foundation.

Each year, the Foundation invites cancer institutes around the world to apply for a research grant. Because the SWCRF accepts one application per institute, many cancer centers are encouraged to hold their own peer review process before submitting a proposal.

Once accepted, all grants undergo an intense peer-review process by the Scientific Advisory Board of the SWCRF at the annual scientific review, held in the spring. Grant recipients are expected to present a progress report of their research findings to the Scientific Advisory Board the next year for critique.

Funded investigators become a part of the Foundation's unique "Institute Without Walls," and are expected to share their findings at the SWCRF annual scientific review. Ongoing funding is contingent upon completion of the specific aims outlined in the research proposal and successful grantees may be eligible for multi-year funding.

The collaborative research grants range between $60,000 and $120,000. Each individual research grantees receives $100,000.

"This year's grant application pool included many highly-respected cancer researchers from institutes all over the globe, making it a very competitive review process," said Gwen Darien, the executive director of the SWCRF. "We are truly thrilled to be able to fund so many qualified individuals and are excited to see the results of such promising research."

The 2010-2011 collaborative research grant recipients are:The 2010-2011 individual research grant recipients are:
-end-
About the Samuel Waxman Cancer Research Foundation

The Samuel Waxman Cancer Research Foundation is an international organization dedicated to curing and preventing cancer. The Foundation is a pioneer in cancer research, focusing on uncovering the causes of cancer and reprogramming cancer cells.

We dedicate ourselves to delivering tailored, minimally toxic treatments to patients. Our mission is to eradicate cancer by bridging the gap between lab science and the patient.

Through our collaborative group of world-class scientists, the Institute Without Walls, investigators share information and tools to speed the pace of cancer research. Since its inception in 1976, the SWCRF has awarded more than $70 million to support the work of more than 170 researchers across three continents. For more information, visit www.waxmancancer.org.

Samuel Waxman Cancer Research Foundation

Related Cancer Research Articles from Brightsurf:

As cancer has evolved, it is time for cancer research to do the same
Marking Lung Cancer Awareness month, a new study investigates the extent to which human-based, non-animal approaches are supplanting animal models in cancer research - comparing number of publications, funding, and publications associated with clinical trials between xenograft models and human organoids.

New liver cancer research targets non-cancer cells to blunt tumor growth
'Senotherapy,' a treatment that uses small molecule drugs to target ''senescent'' cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.

Blueprint to beat cancer launched today by World Cancer Research Fund (WCRF)
Overweight and obesity increase cancer risk. A new report published today by World Cancer Research Fund (WCRF), and presented at the European Congress on Obesity in Vienna, shows that overweight or obesity is a cause of at least 12 cancers, five more than WCRF findings a decade ago.

Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.

UA Cancer Center research team explores anti-breast cancer properties of soy
Genistein, a major compound in soy foods, might aid in the proper functioning of a gene that can malfunction to cause breast cancer.

Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.

The potential consequences for cancer care and cancer research of Brexit
Cancer leaders highlight main fears for patient care, treatment and research in a post-Brexit world.

Cancer Research UK announces Grand Challenge teams to answer biggest questions in cancer
Cancer Research UK today announces that four international teams are the first recipients of its global £100 million Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.

Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.

Leading cancer research organizations to host cancer immunotherapy conference
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will sponsor the second International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel (811 7th Ave., New York, NY 10019) and the New York Hilton Midtown ( 1335 Avenue of the Americas, New York, NY 10019), Sept.

Read More: Cancer Research News and Cancer Research Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.